deferoxamine and Acute Hemolytic Transfusion Reaction studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Research Excerpts

Excerpt	Relevance	Reference
"We compared 48-hour urinary iron excretion after a twice-daily subcutaneous bolus injection of deferoxamine and after 12 hours of subcutaneous continuous infusion of the drug in 27 patients with iron overload (mean age, 55."	9.09	Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. ( Aprili, G; Borgna-Pignatti, C; de Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 2000)
"For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation."	8.83	Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006)
"Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions."	8.83	Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006)
" Iron removal in transfusional iron overload is achieved using chelation therapy with the chelating drugs deferoxamine (DF) and deferiprone (L1)."	8.80	Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ( Hadjigavriel, M; Kolnagou, A; Kontoghiorghes, GJ; Pattichi, K, 2000)
"We used the Markov model to estimate total additional lifetime costs and quality-adjusted life years (QALYs) gained with deferasirox versus deferoxamine in patients with transfusion-dependent thalassemia."	7.79	A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. ( Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL, 2013)
"Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload."	7.74	Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008)
"To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses."	7.70	Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998)
" The resultant iron overload must be treated with chelation therapy using deferoxamine."	7.69	Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy. ( Berdon, WE; Hurlet-Jensen, A; Piomelli, S; Ruzal-Shapiro, C; Sheth, S, 1997)
"Transfusion-induced hemosiderosis is a serious and potentially life-threatening complication for some patients with sickle cell anemia."	6.67	Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. ( Dixon, DJ; Hambidge, KM; Lane, PA; Mellman, DL; Peterson, VM; Silliman, CC, 1993)
"Reversal of arrhythmia to sinus rhythm was noted in all patients."	5.56	Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020)
"Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy."	5.37	Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011)
"We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction."	5.33	Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006)
"We report the successful treatment of severe heart failure in two patients with beta-thalassemia major with the combined therapy."	5.32	Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004)
"Iron overload was evaluated for 26 beta-thalassemia homozygous patients, and 14 of them were submitted to intensive chelation therapy with high doses of intravenous deferoxamine (DF)."	5.31	Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. ( Boturao-Neto, E; Marcopito, LF; Zago, MA, 2002)
"The randomized comparison of deferasirox to deferoxamine for myocardial iron removal in patients with transfusion-dependent anemias (CORDELIA) gave the opportunity to assess relative prevalence and body distribution of iron overload in screened patients."	5.20	Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. ( Aydinok, Y; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Pennell, DJ; Piga, A; Porter, JB; Quebe-Fehling, E; Viprakasit, V; Yesilipek, A, 2015)
" We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients."	5.20	Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. ( Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC, 2015)
"We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years."	5.17	Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. ( Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y, 2013)
"Deferoxamine (DFO) is an iron chelator used to treat iron overload in patients receiving chronic blood transfusions, and is usually administered as overnight subcutaneous infusions."	5.14	Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results. ( Bachir, D; Bisot-Locard, S; Gardembas-Pain, M; Hacini, M; Merlat-Guitard, A; Pégourié-Bandelier, B; Thuret, I, 2009)
" In 18 requiring thyroxine supplementation for hypothyroidism, 10 were able to discontinue, and four reduced their thyroxine dose."	5.14	Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. ( Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I, 2010)
" The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and deferoxamine (DFO) in reducing transfusional iron overload compared to either drug alone and to assess the safety and tolerability of DFP."	5.13	Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. ( El-Beshlawy, A; Eltagui, M; Hamdy, M; Hoffbrand, AV; Manz, C; Mostafa, A; Naja, M; Shaker, O; Sharaf, I; Sobh, H; Taher, A; Tarabishi, C; Youssry, I, 2008)
" We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications."	5.12	Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006)
"We compared 48-hour urinary iron excretion after a twice-daily subcutaneous bolus injection of deferoxamine and after 12 hours of subcutaneous continuous infusion of the drug in 27 patients with iron overload (mean age, 55."	5.09	Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. ( Aprili, G; Borgna-Pignatti, C; de Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 2000)
"Desferrioxamine is the recommended first-line therapy for iron overload in people with thalassaemia major and deferiprone or deferasirox are indicated for treating iron overload when desferrioxamine is contraindicated or inadequate."	4.89	Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013)
" In 2005, the Food and Drug Administration approved the labeling for deferasirox for the treatment of chronic overload due to transfusional hemosiderosis."	4.84	Deferasirox. ( Stumpf, JL, 2007)
"Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions."	4.83	Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006)
"For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation."	4.83	Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006)
" Iron removal in transfusional iron overload is achieved using chelation therapy with the chelating drugs deferoxamine (DF) and deferiprone (L1)."	4.80	Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ( Hadjigavriel, M; Kolnagou, A; Kontoghiorghes, GJ; Pattichi, K, 2000)
"In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39."	3.83	Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016)
"We used the Markov model to estimate total additional lifetime costs and quality-adjusted life years (QALYs) gained with deferasirox versus deferoxamine in patients with transfusion-dependent thalassemia."	3.79	A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. ( Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL, 2013)
"Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion-dependent thalassemia."	3.76	Deferiprone. ( Longo, F; Massano, D; Piga, A; Roggero, S; Salussolia, I; Serra, M, 2010)
"In iron overload conditions, plasma contains non-transferrin bound iron species, collectively referred to as plasma NTBI."	3.76	Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. ( Eccleston, J; Evans, P; Hider, RC; Kayyali, R; Porter, JB, 2010)
"Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload."	3.74	Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008)
"Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major."	3.73	Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006)
"The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination."	3.73	Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006)
"Compliance with parenteral administration of deferoxamine is often poor in thalassemic patients with iron overload."	3.71	Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients. ( Becker, A; Girot, R; Hagège, I; Kanfer, A; Kerdaffrec, T, 2001)
"To examine the potential clinical usefulness of the hexadentate phenolic aminocarboxylate iron chelator N, N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid (HBED) for the chronic treatment of transfusional iron overload, we compared the iron excretion induced by subcutaneous (SC) injection of HBED and deferoxamine (DFO), the reference chelator, in rodents and primates."	3.70	HBED: A potential alternative to deferoxamine for iron-chelating therapy. ( Bergeron, RJ; Brittenham, GM; Wiegand, J, 1998)
"To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses."	3.70	Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998)
" The resultant iron overload must be treated with chelation therapy using deferoxamine."	3.69	Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy. ( Berdon, WE; Hurlet-Jensen, A; Piomelli, S; Ruzal-Shapiro, C; Sheth, S, 1997)
"Deferoxamine is still today the only preventive and curative treatment of transfusional hemochromatosis."	3.68	[Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)]. ( Clairicia, M; de Montalembert, M; Girot, R; Hannedouche, T; Jan, D; Sidi, D, 1992)
"Aluminum-associated osteomalacia and transfusion-induced hemosiderosis developed in an anephric patient receiving long-term maintenance treatment with continuous ambulatory peritoneal dialysis."	3.67	Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis. ( Kurtz, SB; McCarthy, JT; Mussman, GV, 1987)
" Deferoxamine-induced urinary excretion of iron was considerably less than that reported in patients with thalassemia major who were receiving regular blood transfusions."	3.66	Iron burden in sickle cell anemia. ( O'Brien, RT, 1978)
"Adult patients with transfusional hemosiderosis were given ascorbic acid and treated with the iron chelator, desferrioxamine B."	3.65	Treatment of iron overload in adults with continuous parenteral desferrioxamine. ( Bunn, HF; Cooper, B; Moloney, WC; Nathan, DG; Propper, RD; Rosenthal, DS, 1977)
"Neutropenia and agranulocytosis were also detected, suggesting needing of strict hematological control."	2.80	Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. ( Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A, 2015)
" We conclude that the short-term use of L1, with or without DFO, was safe and efficacious in our Chinese patient cohort."	2.72	A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. ( Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO, 2006)
"Transfusion-induced hemosiderosis is a serious and potentially life-threatening complication for some patients with sickle cell anemia."	2.67	Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. ( Dixon, DJ; Hambidge, KM; Lane, PA; Mellman, DL; Peterson, VM; Silliman, CC, 1993)
" Efforts to increase its oral bioavailability are now in progress."	2.67	Results from a phase I clinical trial of HBED. ( Giardina, PJ; Grady, RW; Hilgartner, MW; Salbe, AD, 1994)
"Iron overload is one of the major causes of morbidity and death in patients undergoing chronic transfusion therapy."	2.48	Iron chelation therapy in the management of transfusion-related cardiac iron overload. ( Fernandes, JL, 2012)
"Deferiprone is a three-times-daily oral iron chelator, but has limited availability in the United States."	2.44	Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. ( Baladi, JF; Coates, TD; Delea, TE; Edelsberg, J; Phatak, PD; Sofrygin, O; Thomas, SK, 2007)
"If untreated, iron overload is responsible for heart, liver and endocrine diseases."	2.42	Pharmacotherapy of iron overload in thalassaemic patients. ( Ceci, A; De Mattia, D; De Sanctis, V; Felisi, M, 2003)
" This substance is well absorbed orally and has been shown to enhance the excretion of ferric ion in iron loaded rats."	2.36	[Iron chelation. Biological significance and medical application]. ( Peter, HH, 1983)
"Hemochromatosis is a syndrome which, when fully expressed, is manifested by melanoderma , diabetes mellitus, and liver cirrhosis, with iron overload involving parenchymal and reticuloendothelial cells in many organ systems."	2.36	Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. ( Kellermeyer, RW; McLaren, GD; Muir, WA, 1983)
"Reversal of arrhythmia to sinus rhythm was noted in all patients."	1.56	Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020)
"Management of beta-thalassemia major (TM) requires life-long hemotransfusions leading to iron overload."	1.56	Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities. ( Georgiev, PG; Goranov, SE; Goranova-Marinova, VS; Sapunarova, KG, 2020)
"Deferasirox (DFX) is a novel iron chelator that has been shown to have similar efficacy and safety compared with deferoxamine (DFO) in patients with β-thalassemia."	1.39	Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients. ( Javanbakht, M; Karimi, M; Keshtkaran, A; Mashayekhi, A; Nuri, B; Salavati, S, 2013)
"DFX is well tolerable and at least as effective as DFO to maintain safe serum ferritin levels and normal growth progression in chelation-naïve children."	1.38	Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload. ( Aydinok, Y; Oymak, Y; Türker, ZD; Unal, S; Vergin, C; Yesilipek, A; Yildiz, D, 2012)
"Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy."	1.37	Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011)
" This regimen is safe and may be an option for poorly compliant patients with significant iron overload."	1.36	Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. ( Abboud, MR; Disco, D; Holloman, D; Jackson, S; Kalpatthi, R; Kane, I; Laver, JH; Peters, B; Rackoff, E, 2010)
"Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications."	1.36	Combined iron chelation therapy. ( Agus, A; Campus, S; Danjou, F; Galanello, R; Giardina, PJ; Grady, RW, 2010)
"The risk of cardiac death during 1990-1999 and 2000-2008 was compared."	1.36	Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. ( Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K, 2010)
"Comprehensive care for thalassemia major (TM) patients has achieved great advances in the world, yet psychosocial developmental aspects of care in families with afflicted members has made only limited progress."	1.33	Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY; Wu, KH, 2006)
"The parents of 18 thalassemia major patients (under 12 years of age) were interviewed (in two sessions) to determine their feelings, sources of stress, and support during their childrens' disease process."	1.33	Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY, 2006)
" Based on this experience, deferoxamine at doses lower than 50 mg/kg/d was safe for the eyes and slightly toxic to the ears."	1.33	Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. ( Chen, LJ; Chen, SH; Cheng, SY; Liang, DC; Lin, HC; Liu, HC, 2005)
"In a subset of 10 patients with beta-thalassemia major, the hepatic storage iron concentration had been monitored repeatedly for 12-14 years by chemical analysis of tissue obtained by liver biopsy and by magnetic susceptometry."	1.33	Methods for noninvasive measurement of tissue iron in Cooley's anemia. ( Altmann, K; Azabagic, A; Brittenham, GM; Brown, TR; Hordof, AJ; Jensen, JH; Olivieri, NF; Prakash, A; Printz, BF; Sheth, S; Swaminathan, S; Tang, H; Tosti, CL, 2005)
"We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction."	1.33	Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006)
"Eighty-one patients with thalassemia major but no history of cardiac disease underwent quantitative annual LVEF monitoring by radionuclide ventriculography for a median of 6."	1.32	Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. ( Davis, BA; Jarritt, PH; O'Sullivan, C; Porter, JB, 2004)
"We report the successful treatment of severe heart failure in two patients with beta-thalassemia major with the combined therapy."	1.32	Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004)
"Treatment of patients with beta-thalassemia major has improved dramatically during the past 40 years; however, the current clinical status of these patients remains poorly characterized."	1.32	Complications of beta-thalassemia major in North America. ( Cohen, AR; Cunningham, MJ; Macklin, EA; Neufeld, EJ, 2004)
"We report a case of thalassemia major with biopsy-proven pulmonary iron overload, in which thoracic high-resolution computed tomography revealed a morphological-functional correlation consistent with small airway disease."	1.31	Pulmonary iron overload in thalassemia major presenting as small airway disease. ( Khong, PL; Lam, WK; Ooi, GC; Trendell-Smith, NJ; Tsang, KW, 2002)
"Iron overload was evaluated for 26 beta-thalassemia homozygous patients, and 14 of them were submitted to intensive chelation therapy with high doses of intravenous deferoxamine (DF)."	1.31	Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. ( Boturao-Neto, E; Marcopito, LF; Zago, MA, 2002)
"Our patient's unusual presentation of intussusception was secondary to the mass effect caused by lymphoid hyperplasia, specifically hypertrophied Peyer's patches in the ileum caused by Y enterocolitica infection."	1.31	Intussusception due to Yersinia enterocolitica enterocolitis in a patient with beta-thalassemia. ( Hansen, MG; Levy, M; Pearl, G, 2001)
"To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs, and the patient's physical and social well-being."	1.31	Impact of thalassemia major on patients and their families. ( Arana, A; Caro, JJ; Eleftheriou, A; Green, TC; Huybrechts, K; Wait, S; Ward, A, 2002)
"Management of these patients requires proper dosing of desferrioxamine and transfusion therapy, along with regular monitoring of body iron burden and hemoglobin."	1.30	Desferrioxamine ototoxicity in an adult transfusion-dependent population. ( Alberti, PW; Chiodo, AA; Francombe, WH; Sher, GD; Tyler, B, 1997)
"Dobutamine is a sympathomimetic drug (beta 1 agonist) that increases myocardial contractility and at high doses also systolic arterial blood pressure and heart rate."	1.29	Cardiac study by dobutamine stress echocardiography in thalassemic patients. ( Agostini, A; Angelucci, E; Cesaroni, P; Lucarelli, G; Mariotti, E; Sgarbi, E, 1993)
"Twenty one children of beta thalassemia major aged between 2 and 14 years of age on regular blood transfusion were given subcutaneous desferrioxamine."	1.29	Desferrioxamine induced urinary iron excretion in thalassemia. ( Choudhury, P; Dubey, AP; Kumar, S; Puri, RK; Talukdar, B, 1993)
" The dosage and the route of administration (IV, IM, SC) were adapted to the amount of iron transfused and to the nature of the disease."	1.28	[Treatment of post-transfusion iron overload by deferoxamine]. ( de Montalembert, M; Girot, R; Hannedouche, T; Llados, A, 1989)
"When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic."	1.27	Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. ( Boyden, MH; Carley, H; Freedman, MH; Gallant, LA; Gallant, T, 1987)

Research

Studies (258)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Core Study: Cardiac Function After 12 Months of Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular Ejection Fraction (LVEF)

Timeframe	Studies, this research(%)	All Research%
pre-1990	98 (37.98)	18.7374
1990's	44 (17.05)	18.2507
2000's	70 (27.13)	29.6817
2010's	42 (16.28)	24.3611
2020's	4 (1.55)	2.80

Authors	Studies
Georgiev, PG	1
Sapunarova, KG	1
Goranova-Marinova, VS	1
Goranov, SE	1
Chuang, TY	1
Li, JP	1
Weng, TF	1
Wu, KH	7
Chao, YH	1
Pinto, VM	1
Forni, GL	5
Qaderi, S	1
Mousavi, SH	1
Ahmadi, A	1
Arif, S	1
Madadi, S	1
Ayoubi, S	1
Lucero-Prisno, DE	1
Gattermann, N	1
Mirlohi, MS	1
Yaghooti, H	1
Shirali, S	1
Aminasnafi, A	1
Olapour, S	1
Ghosh, K	3
Ho, WL	1
Chung, KP	1
Yang, SS	1
Lu, MY	1
Jou, ST	1
Chang, HH	1
Yang, YL	1
Lin, DT	1
Lin, KH	1
Abdelmoktader, AM	1
Azer, HY	1
Ricchi, P	1
Ammirabile, M	1
Costantini, S	2
Spasiano, A	1
Di Matola, T	1
Cinque, P	1
Casale, M	1
Filosa, A	1
Prossomariti, L	1
Vichinsky, E	3
Torres, M	1
Minniti, CP	1
Barrette, S	1
Habr, D	4
Zhang, Y	1
Files, B	2
Fisher, SA	1
Brunskill, SJ	1
Doree, C	1
Gooding, S	1
Chowdhury, O	1
Roberts, DJ	2
Origa, R	4
Danjou, F	3
Cossa, S	1
Matta, G	1
Bina, P	2
Dessì, C	2
Defraia, E	2
Foschini, ML	2
Leoni, G	2
Morittu, M	2
Galanello, R	4
Dee, CM	1
Cheuk, DK	1
Ha, SY	3
Chiang, AK	1
Chan, GC	3
Tanphaichitr, A	1
Kusuwan, T	1
Limviriyakul, S	1
Atipas, S	1
Pooliam, J	1
Sangpraypan, T	1
Tanphaichitr, VS	1
Viprakasit, V	3
Pennell, DJ	4
Porter, JB	6
Piga, A	8
Lai, YR	1
El-Beshlawy, A	4
Elalfy, M	3
Yesilipek, A	3
Kilinç, Y	3
Musallam, KM	3
Shen, J	2
Aydinok, Y	4
Quebe-Fehling, E	1
Calvaruso, G	1
Vitrano, A	1
Di Maggio, R	1
Lai, E	1
Colletta, G	1
Quota, A	1
Gerardi, C	1
Rigoli, LC	1
Sacco, M	1
Pitrolo, L	1
Maggio, A	1
Ünal, Ş	2
Tezcan, İ	1
Güçer, Ş	1
Boyraz, MS	1
Çağdaş, D	1
Uçkan Çetinkaya, D	1
Kattamis, A	2
Cappellini, MD	5
Perrotta, S	1
Karakas, Z	1
Constantinovici, N	1
Moi, P	1
Follesa, I	1
Zappu, A	2
Cunico, A	1
Civolani, A	1
Podda, RA	1
Wood, JC	2
Pressel, S	1
Rogers, ZR	1
Odame, I	1
Kwiatkowski, JL	2
Lee, MT	2
Owen, WC	1
Cohen, AR	2
St Pierre, T	1
Heeney, MM	1
Schultz, WH	1
Davis, BR	1
Ware, RE	1
Nijjar, PS	1
Vongooru, H	1
Tamene, A	1
Valeti, U	1
Masri, C	1
Poggi, M	1
Sorrentino, F	1
Pugliese, P	1
Smacchia, MP	1
Daniele, C	1
Equitani, F	1
Terlizzi, F	1
Guitarrini, MR	1
Monti, S	1
Maffei, L	1
Losardo, A	1
Pasin, M	1
Toscano, V	1
Taher, A	4
Kontoghiorghes, GJ	6
McLeod, C	1
Fleeman, N	1
Kirkham, J	1
Bagust, A	1
Boland, A	1
Chu, P	1
Dickson, R	1
Dundar, Y	1
Greenhalgh, J	1
Modell, B	4
Olujohungbe, A	1
Telfer, P	1
Walley, T	1
Luckie, M	1
Irwin, B	1
Nair, S	1
Greenwood, J	1
Khattar, R	1
Adamkiewicz, TV	1
Abboud, MR	2
Paley, C	1
Olivieri, N	1
Kirby-Allen, M	1
Casella, JF	1
Alvarez, OA	1
Barredo, JC	1
Iyer, RV	1
Kutlar, A	1
McKie, KM	1
McKie, V	1
Odo, N	1
Gee, B	2
Woods, GM	1
Coates, T	2
Wang, W	1
Adams, RJ	1
Farmaki, K	1
Tzoumari, I	1
Pappa, C	1
Chouliaras, G	2
Berdoukas, V	3
Thuret, I	1
Hacini, M	1
Pégourié-Bandelier, B	1
Gardembas-Pain, M	1
Bisot-Locard, S	1
Merlat-Guitard, A	1
Bachir, D	1
Rose, C	1
Brechignac, S	1
Vassilief, D	1
Pascal, L	1
Stamatoullas, A	1
Guerci, A	1
Larbaa, D	1
Dreyfus, F	1
Beyne-Rauzy, O	1
Chaury, MP	1
Roy, L	1
Cheze, S	1
Morel, P	1
Fenaux, P	1
Leitch, HA	1
Inati, A	2
Taher, AT	2
Balocco, M	1
Carrara, P	1
Pinto, V	1
Ladis, V	3
Moraitis, P	1
Zannikos, K	1
Berdoussi, E	1
Kattamis, C	3
Waalen, J	1
Evans, P	1
Kayyali, R	1
Hider, RC	2
Eccleston, J	1
Hershko, C	6
Roggero, S	1
Salussolia, I	1
Massano, D	1
Serra, M	1
Longo, F	1
Agus, A	1
Campus, S	1
Giardina, PJ	5
Grady, RW	5
Kalpatthi, R	1
Peters, B	1
Kane, I	1
Holloman, D	1
Rackoff, E	1
Disco, D	1
Jackson, S	1
Laver, JH	1
Abdalla, MY	1
Fawzi, M	1
Al-Maloul, SR	1
El-Banna, N	1
Tayyem, RF	1
Ahmad, IM	1
Smith, GC	1
Alpendurada, F	1
Carpenter, JP	1
Alam, MH	1
Karagiorga, M	1
Aessopos, A	1
Gotsis, ED	1
Tanner, MA	1
Westwood, MA	1
Roughton, M	1
Belhoul, KM	1
Bakir, ML	1
Saned, MS	1
Kadhim, AM	1
Oymak, Y	1
Vergin, C	1
Türker, ZD	1
Yildiz, D	1
Fernandes, JL	1
Shah, J	1
Kurtin, SE	1
Arnold, L	1
Lindroos-Kolqvist, P	1
Tinsley, S	1
Simon, S	1
Athanasiov, PA	1
Jain, R	1
Raymond, G	1
Gilhotra, JS	1
Hoffbrand, AV	6
Keshtkaran, A	1
Javanbakht, M	1
Salavati, S	1
Mashayekhi, A	1
Karimi, M	1
Nuri, B	1
Moayedi, B	1
Gharagozloo, M	1
Esmaeil, N	1
Maracy, MR	1
Hoorfar, H	1
Jalaeikar, M	1
Ooi, GC	2
Khong, PL	2
Lam, WK	1
Trendell-Smith, NJ	1
Tsang, KW	1
Jensen, PD	4
Jensen, FT	4
Christensen, T	4
Nielsen, JL	1
Ellegaard, J	4
Boturao-Neto, E	1
Marcopito, LF	1
Zago, MA	1
Koliakos, G	1
Papachristou, F	1
Koussi, A	1
Perifanis, V	1
Tsatra, I	1
Souliou, E	1
Athanasiou, M	1
Ceci, A	1
Felisi, M	1
De Sanctis, V	1
De Mattia, D	1
Kubota, N	1
Miyazawa, K	1
Shoji, N	1
Sumi, M	1
Nakajima, A	1
Kimura, Y	1
Oshiro, H	1
Ebihara, Y	1
Ohyashiki, K	1
Chang, JS	2
Tsai, CH	3
Peng, CT	7
Kassou, C	1
Berdousi, H	1
Papassotiriou, I	1
Chan, KN	1
Chan, KL	1
Lam, W	1
Ng, I	1
Cunningham, MJ	1
Macklin, EA	1
Neufeld, EJ	2
Davis, BA	1
O'Sullivan, C	1
Jarritt, PH	1
Arora, A	1
Wren, S	1
Gregory Evans, K	1
Olivieri, NF	5
Borgna-Pignatti, C	5
Rugolotto, S	1
De Stefano, P	2
Zhao, H	1
Del Vecchio, GC	1
Romeo, MA	1
Gamberini, MR	1
Ghilardi, R	1
Cnaan, A	1
Franchini, M	3
Mwanda, OW	1
Otieno, CF	1
Abdalla, FK	1
Rees, D	1
Howard, J	1
Hyde, C	1
Alderson, P	1
Brunskill, S	1
Link, G	3
Konijn, AM	2
Cabantchik, ZI	4
Gaziev, J	1
Sodani, P	1
Polchi, P	4
Andreani, M	1
Lucarelli, G	5
Sheth, S	3
Tang, H	1
Jensen, JH	1
Altmann, K	1
Prakash, A	1
Printz, BF	1
Hordof, AJ	1
Tosti, CL	1
Azabagic, A	1
Swaminathan, S	1
Brown, TR	1
Brittenham, GM	3
Chen, SH	1
Liang, DC	1
Lin, HC	1
Cheng, SY	1
Chen, LJ	1
Liu, HC	1
Yilmaz, S	1
Duman, N	1
Ozer, E	2
Kavas, N	1
Oren, H	1
Demircioğlu, F	1
Kumral, A	1
Ozkan, H	1
Irken, G	1
Wu, SF	2
Kolnagou, A	3
Economides, C	1
Eracleous, E	1
Huang, YC	1
Chang, JG	1
Ho, YJ	1
Wang, CH	1
Tsai, FJ	1
Chik, KW	2
Ling, SC	1
Lee, AC	1
Luk, CW	1
Lam, CW	1
Ng, IO	1
Mudiyanse, RM	1
Kuo, HT	2
Tsai, MY	2
Donato, G	1
Bordone, E	1
Lavagetto, A	1
Zanaboni, L	1
Sechaud, R	1
Hewson, N	1
Ford, JM	1
Opitz, H	1
Alberti, D	1
Keijzer, A	1
van der Valk, P	1
Ossenkoppele, GJ	1
van de Loosdrecht, AA	1
Stumpf, JL	1
Delea, TE	2
Edelsberg, J	1
Sofrygin, O	1
Thomas, SK	2
Baladi, JF	3
Phatak, PD	2
Coates, TD	2
Hagiwara, M	1
Mohkam, M	1
Shamsian, BS	1
Gharib, A	1
Nariman, S	1
Arzanian, MT	1
Manz, C	1
Naja, M	1
Eltagui, M	1
Tarabishi, C	1
Youssry, I	1
Sobh, H	1
Hamdy, M	1
Sharaf, I	1
Mostafa, A	1
Shaker, O	1
Pakbaz, Z	1
Onyekwere, O	1
Porter, J	1
Swerdlow, P	1
Lane, P	1
Mueller, BU	1
Coïc, L	1
Fischer, R	1
Marks, P	1
Rofail, D	1
Abetz, L	1
Kondur, AK	1
Li, T	1
Vaitkevicius, P	1
Afonso, L	1
Thompson, RB	1
Owen, DM	1
Bell, WN	1
Cohen, A	4
Witzleben, C	1
Schwartz, E	1
Green, R	2
Lamon, J	1
Curran, D	1
Jacobs, A	2
Ting, WC	1
Fitsialos, J	1
Sinopoulou, C	1
Davies, SC	3
Marcus, RE	2
Hungerford, JL	1
Miller, MH	1
Arden, GB	1
Huehns, ER	2
Bantock, HM	1
Underwood, SR	1
Walton, S	1
Peter, HH	1
Hehlmann, R	1
Schmitz, H	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox[NCT03358498]		75 participants (Anticipated)	Observational	2017-12-01	Not yet recruiting
A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions[NCT00600938]	Phase 2	197 participants (Actual)	Interventional	2007-11-30	Completed
Phase II, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Patients With Severe Cardiac Iron Overload Due to Chronic Blood Transfusion (HYP[NCT01254227]	Phase 2	60 participants (Actual)	Interventional	2011-01-31	Completed
[NCT00000592]	Phase 3	0 participants	Interventional	1994-07-31	Completed
[NCT00006182]	Phase 3	0 participants	Interventional	2000-07-31	Completed
Platelet Changes in Cases of Chronic Iron Over Load[NCT04329286]		50 participants (Anticipated)	Observational	2020-04-01	Not yet recruiting
Platelet Changes in Cases of Iron Overload(IO)[NCT04329377]		50 participants (Anticipated)	Observational	2020-04-01	Not yet recruiting
Prospective Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut University Children Hospital (AUCH)[NCT05303506]		50 participants (Anticipated)	Observational	2022-07-02	Not yet recruiting
Thalassemia Clinical Research Network (TCRN)[NCT00000623]		1,000 participants (Anticipated)	Observational	2000-07-31	Completed
Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901]		150 participants (Actual)	Observational	2009-12-31	Completed
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015]	Early Phase 1	55 participants (Actual)	Interventional	2013-03-15	Completed
Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients[NCT00350662]	Phase 3	95 participants (Actual)	Interventional	2002-01-31	Completed
[NCT00000595]	Phase 2	0 participants	Interventional	1978-01-31	Completed
The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631]	Phase 2	19 participants (Actual)	Interventional	2016-02-29	Completed
Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.[NCT00469560]	Phase 3	158 participants (Actual)	Interventional	2007-06-30	Completed
Predictive Value of Epicardial Fat Thickness for Disease Severity in Coronary Artery Disease Patients[NCT03308539]		200 participants (Anticipated)	Observational	2017-11-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

An absolute change from baseline in LVEF after 12 months treatment with deferasirox and compared to.DFO was tested using an analysis of covariance model including baseline left ventricular ejection fraction (LVEF) as a covariate. (NCT00600938)
Timeframe: 12 Month

Core Study: Cardiac Function After 6 Months of Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular Ejection Fraction (LVEF)

Intervention	Percent (Least Squares Mean)
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL	-0.5
Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO	-0.0

An absolute change from baseline in LVEF after 6 months treatment with deferasirox and DFO was summarized (NCT00600938)
Timeframe: 6 Month

Core Study: Cardiac Function and the Proportion of Patients Dropping Out Due to Cardiac Dysfunction After Treatment With Deferasirox vs. Deferoxamine

Intervention	Percent (Mean)
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL	-0.95
Deferoxamine (DFO). For Extension Labeled as DFO to DFO	-0.37

The number of patients withdrawn from the study due to LVEF <50%, T2* <6 ms or significant decreases in T2* ≥ 33% from baseline was provided per treatment group. (NCT00600938)
Timeframe: 12 Month

Core Study: Change From Baseline in Myocardial T2* (Magnetic Resonance T2-star (T2*) Technique for the Measurement of Tissue Iron) After 12 Months Treatment

Intervention	Participants (Number)
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL	3
Core; Deferoxamine (DFO). For Extension Labeled as DFO to DFO	2

Non- inferiority in efficacy of deferasirox compared to deferoxamine (DFO) in treating cardiac iron overload as measured by T2*. A non-inferiority margin of 0.9 (90%) was applied. Due to limitations in performing heart biopsies, T2* (T2 star), a Magnetic Resonance (MR) relaxation parameter expressed in milliseconds, as is an important tool to noninvasively quantify cardiac iron concentration. Studies have shown that myocardial T2* evaluations may predict cardiac events, e.g., impaired (<56%) left ventricular ejection fraction (LVEF) is prevalent among patients with low T2*: found in 62% of patients with T2*<8 ms; 20% with T2* of 8-12 ms; and in 5% with T2* >12 ms (Tanner 2006) (NCT00600938)
Timeframe: 12 Month

Core Study: Change From Baseline in Myocardial T2* After 6 Months Treatment

Intervention	Millisecond (Geometric Mean)
Core: Deferasirox (ICL)	1.12
Core: Deferoxamine (DFO)	1.07

Summary statistics of T2* ratio Month 6/baseline (NCT00600938)
Timeframe: 6 Month

Core Study: Single and Repeated Dose Pharmacokinetics of Deferasirox, Area Under the Plasma Concentration-time Curve for a Dosing Interval (AUCtau)

Intervention	Ratio (Geometric Mean)
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL	1.04
Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO	1.04

The plasma level of deferasirox (ICL670) obtained in this study was summarized descriptively. Plasma concentration was plotted by patient and by visit. Descriptive statistics included the mean, median, SD, and CV, min and max. deferasirox pharmacokinetics (PK) trough levels over the 12 months of treatment and obtained PK profiles for the 40 mg/kg/day deferasirox dose, area under the plasma concentration-time curve for a dosing interval (AUCtau) (NCT00600938)
Timeframe: 12 Month

Core Study: Single and Repeated Dose Pharmacokinetics of Deferasirox, Maximum Plasma Concentration (Cmax)

Intervention	(h.ng/mL) (Mean)
Deferasirox (ICL). For Extension Labeled as ICL to ICL	2129.70

The plasma level of deferasirox (ICL670) obtained in this study was summarized descriptively. Plasma concentration was plotted by patient and by visit. Descriptive statistics included the mean, median, SD, and CV, min and max. deferasirox pharmacokinetics (PK) trough levels over the 12 months of treatment and obtained PK profiles for the 40 mg/kg/day deferasirox dose, maximum plasma concentration (Cmax) (NCT00600938)
Timeframe: 12 Month

Core Study: Single and Repeated Dose Pharmacokinetics of Deferasirox, Maximum Plasma Concentration (Tmax)

Intervention	umol/L (Mean)
Deferasirox (ICL). For Extension Labeled as ICL to ICL	150.09

The plasma level of deferasirox (ICL670) obtained in this study was summarized descriptively. Plasma concentration was plotted by patient and by visit. Descriptive statistics included the mean, median, SD, and CV, min and max. deferasirox pharmacokinetics (PK) trough levels over the 12 months of treatment and obtained PK profiles for the 40 mg/kg/day deferasirox dose, time to reach maximum plasma concentration (Tmax) (NCT00600938)
Timeframe: 12 Month

Core Study: Cardiac Function After 6 and 12 Months of Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular Mass Indices (LVMI)

Intervention	(h) (Median)
Deferasirox (ICL). For Extension Labeled as ICL to ICL	4.00

An absolute change from baseline in LVMI after 6, and 12 months treatment with deferasirox and DFO was summarized (NCT00600938)
Timeframe: 6 Month, 12 Month

Core Study: Cardiac Function After 6 and 12 Months Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular End Systolic Volume Indices (LVESVI)

Intervention	gram/m^2 (Mean)
	Change from Baseline at 6 Month (n= 85, 73)	Change from Baseline at 12 Month/EOS (n= 91, 81)
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL	1.01	4.13
Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO	3.32	5.25

An absolute change from baseline in LVESVI after 6 and 12 months treatment with deferasirox and DFO was summarized. Changes in cardiovascular magnetic resonance (CMR) measured left ventricular end systolic after 6 and 12 months treatment. Left ventricular (LV) end-systolic volume indexed to body surface area (ESVI) is a simple yet powerful echocardiographic marker of LV remodeling that can be measured easily. Left ventricular (LV) end-systolic volume (ESV) has been shown to be an important determinant of survival after myocardial infarction (MI) (NCT00600938)
Timeframe: 6 Month, 12 Month

Core Study: Core Study: Cardiac Function After 6 and 12 Months of Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular End Diastolic Volume Indices (LVEDVI)

Intervention	Milliliter (Mean)
	Change from baseline at 6 Month (n= 85, 73)	Change from Baseline at 12 Month/EOS (n= 91, 81)
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL	1.8	1.57
Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO	0.88	0.10

An absolute change from baseline in LVEDVI after 6, and 12 months treatment with deferasirox and DFO was summarized (NCT00600938)
Timeframe: 6 Month, 12 Month

Core Study: Safety and Tolerability of Deferasirox vs Deferoxamine Over the 12 Months Treatment Period.

Intervention	Percent (Mean)
	Change from Baseline at 6 Month (n= 85, 73)	Change from Baseline at 12 Month/EOS (n= 91, 81)
Core; Deferasirox (ICL). For Extension Labeled as ICL to ICL	1.81	1.79
Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO	1.48	1.10

Number of patients with adverse events, serious adverse events and death (NCT00600938)
Timeframe: 12 Month

Core Study: Single and Repeated Dose Pharmacokinetics of Deferasirox, Time Points of Concentration Data

Intervention	Participants (Number)
	At least one AE	Serious Adverse Events	Death. None were considered related to study drug.
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL	65	10	1
Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO	69	10	1

The plasma level of deferasirox (ICL670) obtained in this study was summarized descriptively. Plasma concentration was plotted by patient and by visit. For trough concentration assessments, a 2-mL blood sample was to be taken on arrival at the study site, i.e. prior to the patient receiving the daily deferasirox dose (pre-dose blood sample). A second 2-mL blood sample was to be taken 2 hours later (post-dose sample). At all other visits (Visits 3 - 14), a pre-dose sample was to be taken. For PK profile assessments, 3 blood samples were taken after 1, 2, and 4 hours post-dose in addition to the 2-mL pre-dose (NCT00600938)
Timeframe: Month 1 and month 2 (pre-dose, 1,2 and 4 hours post-dose)

Extension Study: Cardiac Function From Baseline to Month 24 by Change in Left Ventricular Ejection Fraction (LVEF)

Intervention	(umol/L) (Mean)
	Month 1, 0 hour (predose)	Month 1, 1 hour (post dos)	Month 1, 2 hour (post dose)	Month 1, 4 hour (post dose)	Month 2, 0 hour (predose)	Month 2, 1 hour (post dose)	Month 2, 2 hour (post dose)	Month 2, 4 hour (post dose)
Deferasirox (ICL). For Extension Labeled as ICL to ICL	32.25	96.32	136.47	133.33	38.66	119.48	177.19	180.76

Cardiac function endpoints (LVEF) obtained by CMR at baseline, Months 6, 12, 18 and 24 were summarized by means of descriptive statistics. These analyses were conducted for the measured values as well as for the absolute changes from baseline (NCT00600938)
Timeframe: Months 6, 12, 18 and 24

Extension Study: Cardiac Function From Baseline to Month 24 by Change in Left Ventricular End Diastolic Volume Indices (LVEDVI)

Intervention	Percent (Mean)
	Month 6 (n=71,26,40,1)	Month 12 (n= 66,29,42,1)	Month 18 (n=68,26,39,1 )	Month 24 (n= 63,25,33,1)
Extension: DFO to DFO	-1.8	0.3	-0.8	-0.6
Extension: DFO to ICL	0.1	0.0	-1.3	0.2
Extension: ICL to DFO	-1.0	0	-10.0	-18.0
Extension: ICL to ICL	-1.1	-0.5	-0.1	0.6

Cardiac function endpoint (LVEDVI ) obtained by CMR at baseline, Months 6, 12, 18 and 24 were summarized by means of descriptive statistics. These analyses were conducted for the measured values as well as for the absolute changes from baseline (NCT00600938)
Timeframe: Months 6, 12, 18 and 24

Extension Study: Cardiac Function From Baseline to Month 24 by Change in Left Ventricular End Systolic Volume Indices (LVESVI)

Intervention	mL/m^2 (Mean)
	Month 6 (n=69,26,40,1)	Month 12 (n=64,28,40,1)	Month 18 (n=67,24,35,1)	Month 24 (n=60,23,33,0)
Extension: DFO to DFO	3.5	-0.6	4.2	9.5
Extension: DFO to ICL	0.5	3.0	8.3	5.4
Extension: ICL to DFO	1.0	4.0	36.0	NA
Extension: ICL to ICL	2.0	2.0	6.5	3.4

Cardiac function endpoints (LVESVI) obtained by CMR at baseline, Months 6, 12, 18 and 24 were summarized by means of descriptive statistics. These analyses were conducted for the measured values as well as for the absolute changes from baseline (NCT00600938)
Timeframe: Months 6, 12, 18 and 24

Extension Study: Cardiac Function From Baseline to Month 24 by Change in Left Ventricular Mass Indices (LVMI)

Intervention	mL/m^2 (Mean)
	Month 6 (n=69,26,40,1)	Month 12 (n=64,28,40,1 )	Month 18 (n=67,24,35,1 )	Month 24 (n=60,23,33,0 )
Extension: DFO to DFO	3.4	-0.8	2.8	4.3
Extension: DFO to ICL	0	0.6	4.1	1.7
Extension: ICL to DFO	1	2	28.0	NA
Extension: ICL to ICL	1.7	1.5	2.4	1.6

Cardiac function endpoints (LVMI) obtained by CMR at baseline, Months 6, 12, 18 and 24 were summarized by means of descriptive statistics. These analyses were conducted for the measured values as well as for the absolute changes (NCT00600938)
Timeframe: Months 6, 12, 18 and 24

Extension Study: Change From Baseline in Myocardial T2* After 24 Months Treatment

Intervention	gram/m^2 (Mean)
	Month 6 (n=69,26,40,1)	Month 12 (n=64,28,40,1)	Month 18 (n=67,24,35,1)	Month 24 (n=60,23,33,0)
Extension: DFO to DFO	1.8	9.1	-0.1	6.7
Extension: DFO to ICL	3.2	3.4	4.0	10.3
Extension: ICL to DFO	-6.0	1	37.0	NA
Extension: ICL to ICL	1.4	4.2	4.8	5.6

The measured T2* values, the ratio (post-baseline / baseline T2*) at Month 6, 12, 18 and 24 was summarized for FAS population along with two-sided 95% CIs. The geometric means of the ratio was presented for all treatment groups (NCT00600938)
Timeframe: Months 6, 12, 18 and 24

Extension Study: Change in Liver Iron Concentration (LIC) From Baseline at Month 24

Intervention	Ratio (Geometric Mean)
	Month 6 (n=71,26,40,1)	Month 12(n=66, 29, 41, 1)	Month 18 (n=68, 26, 39, 1)	Month 24 (n=63, 25, 33, 1)
Extension : ICL to ICL	1.06	1.17	1.24	1.38
Extension; DFO to ICL	1.03	1.07	1.13	1.21
Extension: DFO to DFO	1.05	1.06	1.18	1.33
Extension: ICL to DFO	1.00	1.17	1.05	1.11

Results of liver iron content (LIC) measurements by MRI was summarized by descriptive statistics. The absolute value and the absolute change from baseline in LIC at Months 6, 12, 18 and 24 were provided by treatment group. (NCT00600938)
Timeframe: Months 6, 12, 18 and 24

Extension Study: Change in Serum Ferritin From Baseline by Month

Intervention	mg Fe/g dw (Mean)
	Month 6 (n=71,26,38,1)	Month 12 (n=69,29,40,1)	Month 18 (n=70,23,38,1)	Month 24 (n=60,24,33,1)
Extension: DFO to DFO	-12.66	-19.44	-26.09	-26.02
Extension: DFO to ICL	-6.30	-7.98	-10.87	-10.96
Extension: ICL to DFO	-3.80	-3.90	-2.90	-3.20
Extension: ICL to ICL	-4.56	-10.22	-12.26	-15.74

Serum ferritin values was summarized by descriptive statistics. Absolute value and the absolute change from baseline in serum ferritin by month was provided by treatment group. (NCT00600938)
Timeframe: Months 6, 12, 18 and 24

Extension Study: The Cardiac Iron Concentration From T2* Values

Intervention	ug/L (Mean)
	Month 6 (n=72,28,38,0)	Month 12 (n=70,29,40,1)	Month 18 (n=66,24,39,1)	Month 24 (n=59,24,30,0)
Extension: DFO to DFO	-1307.14	-1877.00	-2426.92	-2724.00
Extension: DFO to ICL	-1054.87	-1223.73	-1494.82	-1513.23
Extension: ICL to DFO	NA	-498.00	-1067.00	NA
Extension: ICL to ICL	-626.10	-988.46	-1962.14	-2239.03

Cardiac iron concentration (derived from T2* values) at baseline, Months 6, 12, 18 and 24 were summarized by descriptive statistics. The absolute change from baseline at Months 6, 12, 18 and 24 were also summarized by treatment group. Lliver iron concentration is expressed in units (mg of iron / g of liver tissue dry weight (dw) (NCT00600938)
Timeframe: Months 6, 12, 18 and 24

Change in Cardiac Iron Content From Baseline to Month 12

Intervention	mg Fe/g dw (Mean)
	Month 6 (n=71,26,40,1)	Month 12 (n=66,29,41,1)	Month 18 (n=68,26,39,1)	Month 24 (n=63,25,33,1)
Extension: DFO to DFO	-0.12	-0.12	-0.45	-0.69
Extension: DFO to ICL	-0.08	-0.14	-0.20	-0.34
Extension: ICL to DFO	0	-0.77	-0.24	-0.52
Extension: ICL to ICL	-0.12	-0.38	-0.47	-0.70

Cardiac T2* is the most sensitive and reproducible test in detecting myocardial iron load. A cardiac T2* value of <10 ms is defined as severe cardiac iron overload. Participants who do not have baseline T2* or do not have any post-baseline T2* are excluded from the analysis. (NCT01254227)
Timeframe: From Baseline to Month 12

Time to Achieve From Baseline (FAS) of at Least 10% at Month 24

Intervention	ratio (Geometric Mean)
All Participants	1.09

Time from date of start of study treatment to date when first achieving T2* ≥ 10 ms (but at least 10% relative increase from baseline) was summarized using the reverse Kaplan-Meier estimates (1 - Kaplan-Meier estimates) for the FAS. (NCT01254227)
Timeframe: At 24 months

Cardiac Iron Concentration Levels From Baseline and at Month 6, 12, 18 and 24

Intervention	milliseconds/ms (Median)
All Participants	722.0

Cardiac iron concentration (mg Fe/g dw) was quantified using the formula (cardiac iron concentration (mg Fe/g dw) = 45 * T2* (ms) ^ (-1.22) and analyzed over time. (NCT01254227)
Timeframe: From the Baseline, Month 6, 12, 18 and Month 24

Change in Cardiac Iron Content From Baseline to Month 6,18 and 24

Intervention	mg Fe/g dw (Mean)
	Baseline	Month 6	Month 12	Month 18	Month 24
All Participants	4.18	4.31	3.93	3.51	3.14

The change in cardiac iron content was calculated as ratio of Cardiac T2* at different time points; the efficacy endpoint analyses were performed on the Full Analysis Set (FAS). (NCT01254227)
Timeframe: From Baseline to Months 6, 18 and 24

Change in Left Ventricular Ejection Fraction (LVEF) From Baseline to Month 6, 12, 18 and 24

Intervention	ratio (Geometric Mean)
	Month 6	Month 18	Month 24
All Participants	1.02	1.17	1.30

Magnetic resonance imaging (MRI)-measured cardiac T2* and cardiac function reflected by left and right ventricle ejection fraction. A standardized MRI protocol for T2* acquisition technique will be used in the centers. Images will be reviewed centrally by an expert MRI reader. (NCT01254227)
Timeframe: From the Months 6, 12, 18 and 24

Change in Right Ventricular Ejection Fraction (RVEF) From Baseline to Month 6, 12, 18 and 24

Intervention	Percent Ejection Fraction (Mean)
	Baseline	Month 6	Month 12	Month 18	Month 24
All Participants	66.5	0.1	-0.2	0.6	0.9

Percentage of Participants With T2*>=10 ms and at Least 10% Relative Increase From Baseline at Month 6, 12, 18 and 24

Intervention	Percent Ejection Fraction (Mean)
	Baseline	Month 6	Month 12	Month 18	Month 24
All Participants	67.1	-1.2	-1.6	-2.1	-1.4

The number of evaluable participants at each visit were used as the denominator for the calculation of proportion at each visit. (NCT01254227)
Timeframe: From the Months 6, 12, 18 and 24

Reviews

Trials

Other Studies

185 other studies available for deferoxamine and Acute Hemolytic Transfusion Reaction

Article	Year
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series. International journal of molecular sciences, 2020, Nov-20, Volume: 21, Issue:22 Topics: Adult; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Chelation Therapy; Deferoxamine; Drug	2020
Iron overload in myelodysplastic syndromes (MDS). International journal of hematology, 2018, Volume: 107, Issue:1 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Erythropoiesis; Hepcidins; Humans; Intestin	2018
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane database of systematic reviews, 2013, Aug-21, Issue:8 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents;	2013
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:13 Topics: Administration, Oral; Benzoates; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron C	2008
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2009, Volume: 13, Issue:1 Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferipro	2009
Iron chelation therapy in the management of transfusion-related cardiac iron overload. Transfusion, 2012, Volume: 52, Issue:10 Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferip	2012
Management of transfusion-related iron overload in patients with myelodysplastic syndromes. Clinical journal of oncology nursing, 2012, Volume: 16 Suppl Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating A	2012
Pharmacotherapy of iron overload in thalassaemic patients. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:10 Topics: Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; I	2003
Recent acquisitions in the management of iron overload. Annals of hematology, 2005, Volume: 84, Issue:10 Topics: Deferoxamine; Humans; Infusion Pumps; Iron Chelating Agents; Iron Overload; Transfusion Reaction	2005
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane database of systematic reviews, 2005, Oct-19, Issue:4 Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone	2005
Objectives and mechanism of iron chelation therapy. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic;	2005
T2* magnetic resonance and myocardial iron in thalassemia. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Th	2005
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood, 2006, May-01, Volume: 107, Issue:9 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis	2006
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone;	2006
Deferasirox. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Mar-15, Volume: 64, Issue:6 Topics: Adult; Benzoates; Child; Deferasirox; Deferoxamine; Hematologic Diseases; Hemosiderosis; Humans; Iro	2007
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion, 2007, Volume: 47, Issue:10 Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cost of Illness; Deferiprone; Deferoxamine; Humans	2007
Quantification of myocardial iron overload by cardiovascular magnetic resonance imaging T2* and review of the literature. Clinical cardiology, 2009, Volume: 32, Issue:6 Topics: Animals; Cardiomyopathies; Deferoxamine; Early Diagnosis; Female; Heart Failure; Hemosiderosis; Huma	2009
Treatment of iron overload. Seminars in liver disease, 1984, Volume: 4, Issue:3 Topics: Bloodletting; Carcinoma, Hepatocellular; Deferoxamine; Hemochromatosis; Humans; Liver; Liver Cirrhos	1984
[Iron chelation. Biological significance and medical application]. Schweizerische medizinische Wochenschrift, 1983, Oct-08, Volume: 113, Issue:40 Topics: Animals; Bacterial Infections; Catechols; Deferoxamine; Diabetes Mellitus; Enterobactin; Female; Hum	1983
Clinical removal of iron. Annual review of medicine, 1982, Volume: 33 Topics: Adult; Anemia, Sideroblastic; Bloodletting; Carcinoma, Hepatocellular; Deferoxamine; Diet; Erythropo	1982
Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Critical reviews in clinical laboratory sciences, 1983, Volume: 19, Issue:3 Topics: Anemia, Hypochromic; Biological Transport; Bloodletting; Chelating Agents; Deferoxamine; Disease Mod	1983
Recognition and treatment of iron overload. Advances in internal medicine, 1980, Volume: 26 Topics: Adult; Blood Grouping and Crossmatching; Bloodletting; Costs and Cost Analysis; Deferoxamine; Ethyle	1980
[Hemochromatosis]. Annales de medecine interne, 1981, Volume: 132, Issue:6 Topics: Alleles; Biopsy; Bloodletting; Bone Marrow Examination; Chelating Agents; Deferoxamine; Diet; Genes,	1981
Problems related to treatment of beta-thalassaemia major. Paediatrician, 1982, Volume: 11, Issue:3-4 Topics: Adolescent; Adult; Bone Diseases; Child; Child, Preschool; Deferoxamine; Encephalitis; Female; Hormo	1982
Clinical manifestations and therapy of transfusional haemosiderosis. Bailliere's clinical haematology, 1994, Volume: 7, Issue:4 Topics: Adolescent; Adult; Chelation Therapy; Deferoxamine; Endocrine System Diseases; Female; Heart Disease	1994
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Seminars in hematology, 1995, Volume: 32, Issue:4 Topics: Adolescent; Adult; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Growth Disorders; Heari	1995
Results of long-term iron-chelating therapy. Acta haematologica, 1996, Volume: 95, Issue:1 Topics: Adolescent; Adult; Deferoxamine; Female; Ferritins; Hemosiderosis; Humans; Iron Chelating Agents; Ma	1996
[Secondary iron overload]. Annales de biologie clinique, 1998, Volume: 56 Spec No Topics: Adult; Anemia, Dyserythropoietic, Congenital; Anemia, Hemolytic; Bone Marrow Examination; Chelating	1998
Oral iron chelation therapy for thalassaemia: an uncertain scene. British journal of haematology, 2000, Volume: 111, Issue:1 Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron	2000
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfusion science, 2000, Volume: 23, Issue:3 Topics: Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reac	2000
Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. Vox sanguinis, 2000, Volume: 79, Issue:3 Topics: Anemia, Hemolytic; beta-Thalassemia; Blood Group Incompatibility; Blood Transfusion; Cardiovascular	2000
Iron overload: clinical and pathologic aspects in pediatrics. Seminars in hematology, 1977, Volume: 14, Issue:1 Topics: Abnormalities, Multiple; Adolescent; Adult; Ascorbic Acid Deficiency; Bloodletting; Child; Child, Pr	1977
[Sideroblastic anemias]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1978, Issue:84 Topics: Anemia, Sideroblastic; Bone Marrow Cells; Deferoxamine; Female; Ferritins; Ferrochelatase; Folic Aci	1978
Iron chelation therapy for iron loaded patients. British journal of haematology, 1979, Volume: 43, Issue:1 Topics: Animals; Deferoxamine; Humans; Hydroxamic Acids; Iron; Iron Chelating Agents; Rats; Transferrin; Tra	1979
Advances in the use of iron-chelating agents for the treatment of iron overload. Progress in hematology, 1979, Volume: 11 Topics: Adolescent; Adult; Anemia; Child; Child, Preschool; Deferoxamine; Female; Ferritins; Heart; Hemochro	1979
Thalassemia in Britain and Australia. Birth defects original article series, 1976, Volume: 12, Issue:8 Topics: Adolescent; Australia; Chelating Agents; Deferoxamine; Humans; Iron; Liver; Puberty; Thalassemia; Tr	1976
The management of haemoglobinopathies. Bailliere's clinical haematology, 1991, Volume: 4, Issue:2 Topics: Adolescent; Anemia, Sickle Cell; Bone Marrow Transplantation; Chelation Therapy; Child; Child, Presc	1991
Clinical spectrum of iron overload, novel uses of iron chelators, and potential treatment of pediatric anemias with erythropoietin. Introduction. The American journal of pediatric hematology/oncology, 1990,Spring, Volume: 12, Issue:1 Topics: Anemia; Chelation Therapy; Child; Deferoxamine; Erythrocyte Transfusion; Erythropoietin; Humans; Iro	1990
Treatment of transfusional iron overload. The American journal of pediatric hematology/oncology, 1990,Spring, Volume: 12, Issue:1 Topics: Administration, Oral; Chelating Agents; Deferoxamine; Erythrocyte Transfusion; Hematologic Diseases;	1990
Oral iron chelators. Seminars in hematology, 1990, Volume: 27, Issue:2 Topics: Administration, Oral; Chelation Therapy; Deferoxamine; Humans; Iron Chelating Agents; Thalassemia; T	1990
Current status of iron chelation therapy with deferoxamine. Seminars in hematology, 1990, Volume: 27, Issue:2 Topics: Chelation Therapy; Deferoxamine; Humans; Iron Chelating Agents; Thalassemia; Transfusion Reaction	1990
Management of iron overload in the pediatric patient. Hematology/oncology clinics of North America, 1987, Volume: 1, Issue:3 Topics: Bloodletting; Chelating Agents; Child; Deferoxamine; Humans; Iron; Transfusion Reaction	1987
Detoxification in hemosiderosis. Blood purification, 1985, Volume: 3, Issue:1-3 Topics: Administration, Oral; Adult; Aluminum; Deferoxamine; Hemosiderosis; Humans; Injections, Intravenous;	1985
[Diseases caused by iron metabolism disorders and their therapy]. Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete, 1969, Volume: 50, Issue:3 Topics: Adult; Anemia, Hypochromic; Anti-Glomerular Basement Membrane Disease; Bloodletting; Deferoxamine; D	1969

Article	Year
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. American journal of hematology, 2013, Volume: 88, Issue:12 Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therap	2013
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American journal of hematology, 2015, Volume: 90, Issue:2 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine;	2015
Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. European journal of haematology, 2015, Volume: 95, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Child; Deferoxamine; Female; Humans; Iron; Iron	2015
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. American journal of hematology, 2015, Volume: 90, Issue:7 Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine;	2015
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood, 2015, Jun-18, Volume: 125, Issue:25 Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Female; Heart; Humans; Iron Chelatin	2015
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American journal of hematology, 2015, Volume: 90, Issue:9 Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Pre	2015
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, Nov-19, Volume: 114, Issue:21 Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans;	2009
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, Nov-19, Volume: 114, Issue:21 Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans;	2009
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, Nov-19, Volume: 114, Issue:21 Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans;	2009
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, Nov-19, Volume: 114, Issue:21 Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans;	2009
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. British journal of haematology, 2010, Volume: 148, Issue:3 Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxami	2010
Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results. Hematology (Amsterdam, Netherlands), 2009, Volume: 14, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Chelation Therapy; Child; Cross-Sectional Studies	2009
A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine. European journal of haematology, 2013, Volume: 90, Issue:3 Topics: Adolescent; Adult; Antimicrobial Cationic Peptides; beta-Thalassemia; Deferoxamine; Double-Blind Met	2013
Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood, 2003, Jan-01, Volume: 101, Issue:1 Topics: Adult; Aged; Anemia; Chelation Therapy; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; I	2003
Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica, 2003, Volume: 88, Issue:12 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferiprone; Defe	2003
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Administration, Oral; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Clinical Protocols; Com	2006
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali	2006
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined	2006
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 2006, Volume: 91, Issue:7 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chel	2006
Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Annals of hematology, 2008, Volume: 87, Issue:7 Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferiprone; Deferoxamine; Drug Admin	2008
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta haematologica, 2008, Volume: 119, Issue:3 Topics: Absenteeism; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Child, Pre	2008
Clinical trial of desferrioxamine entrapped in red cell ghosts. Lancet (London, England), 1980, Aug-16, Volume: 2, Issue:8190 Topics: Adult; Aged; Anemia; Anemia, Aplastic; Blood Transfusion; Clinical Trials as Topic; Deferoxamine; Er	1980
Oral desferrioxamine in young patients with thalassaemia. Lancet (London, England), 1981, Jan-03, Volume: 1, Issue:8210 Topics: Administration, Oral; Child, Preschool; Deferoxamine; Hemosiderosis; Humans; Thalassemia; Transfusio	1981
High transfusion in children with beta-thalassemia/Hb E: clinical and laboratory assessment of 18 cases. The Southeast Asian journal of tropical medicine and public health, 1993, Volume: 24 Suppl 1 Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Female; Ferr	1993
Results from a phase I clinical trial of HBED. Advances in experimental medicine and biology, 1994, Volume: 356 Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Deferoxamine; Edetic Acid; Female; Humans; Ir	1994
Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. The Journal of laboratory and clinical medicine, 1993, Volume: 122, Issue:1 Topics: Adolescent; Adult; Anemia, Sickle Cell; Deferoxamine; Dose-Response Relationship, Drug; Double-Blind	1993
Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood, 1997, Aug-01, Volume: 90, Issue:3 Topics: Adolescent; Bone Marrow Transplantation; Chelation Therapy; Child; Combined Modality Therapy; Defero	1997
Combined therapy with deferiprone and desferrioxamine. British journal of haematology, 1998, Volume: 103, Issue:2 Topics: Adolescent; Adult; Aged; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response Relationship, Dr	1998
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood, 2000, May-01, Volume: 95, Issue:9 Topics: Adult; Aged; Chelating Agents; Deferoxamine; Female; Ferritins; Follow-Up Studies; Humans; Infusions	2000
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. European journal of haematology, 2001, Volume: 67, Issue:1 Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; De	2001
Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. Seminars in hematology, 1990, Volume: 27, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug A	1990
Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients. Annals of the New York Academy of Sciences, 1990, Volume: 612 Topics: Administration, Oral; Adult; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridon	1990

Article	Year
Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities. Folia medica, 2020, Jun-30, Volume: 62, Issue:2 Topics: Adult; beta-Thalassemia; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritin	2020
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. Annals of hematology, 2020, Volume: 99, Issue:10 Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati	2020
Transfusion-dependent beta thalassemia in Afghanistan: current evidence amid COVID-19 and future recommendations. Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1 Topics: Afghanistan; beta-Thalassemia; Blood Donors; Blood Transfusion; Comorbidity; COVID-19; Culturally Co	2021
Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major. Annals of hematology, 2018, Volume: 97, Issue:4 Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Blood Transfusion; Chelation Therapy; Combined Moda	2018
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one? The Indian journal of medical research, 2018, Volume: 148, Issue:4 Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov	2018
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi, 2013, Volume: 112, Issue:4 Topics: Benzoates; Child, Preschool; Deferasirox; Deferoxamine; Health Care Costs; Humans; Iron Chelating Ag	2013
Usefulness of pulsed wave tissue doppler imaging in assessment of left ventricular functions in children with beta-thalassemia major. Indian journal of pediatrics, 2013, Volume: 80, Issue:9 Topics: beta-Thalassemia; Chelating Agents; Child; Deferoxamine; Echocardiography, Doppler; Female; Humans;	2013
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters. Annals of hematology, 2014, Volume: 93, Issue:3 Topics: Adult; Aging; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Disease Sus	2014
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Defer	2013
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia. British journal of haematology, 2014, Volume: 167, Issue:3 Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child;	2014
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents. Hemoglobin, 2014, Volume: 38, Issue:5 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone;	2014
Diagnosis: Melanoderma after Hematopoietic Stem Cell Transplantation. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:4 Topics: Antilymphocyte Serum; Busulfan; Deferoxamine; Diagnosis, Differential; Ecchymosis; Humans; Infant; I	2015
Thalassemia major between liver and heart: Where we are now. Blood cells, molecules & diseases, 2015, Volume: 55, Issue:1 Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferiprone; Deferoxam	2015
Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis. Minnesota medicine, 2015, Volume: 98, Issue:7 Topics: Adult; Anemia, Aplastic; Deferiprone; Deferoxamine; Echocardiography; Hemochromatosis; Humans; Iron	2015
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Annals of hematology, 2016, Volume: 95, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe	2016
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin, 2008, Volume: 32, Issue:6 Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone;	2008
Left ventricular non-compaction in identical twins with thalassaemia and cardiac iron overload. European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, 2009, Volume: 10, Issue:4 Topics: beta-Thalassemia; Deferoxamine; Diseases in Twins; Echocardiography; Female; Ferritins; Genetic Pred	2009
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leukemia research, 2010, Volume: 34, Issue:7 Topics: Aged; Aged, 80 and over; Chelation Therapy; Comorbidity; Deferoxamine; Disease Progression; Female;	2010
Iron chelation therapy in MDS: does it improve survival? Leukemia research, 2010, Volume: 34, Issue:7 Topics: Chelation Therapy; Deferoxamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fol	2010
Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood, 2010, Apr-08, Volume: 115, Issue:14 Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans;	2010
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. American journal of hematology, 2010, Volume: 85, Issue:6 Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Defer	2010
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. European journal of haematology, 2010, Volume: 85, Issue:4 Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone;	2010
More pieces to the iron chelation puzzle. Translational research : the journal of laboratory and clinical medicine, 2010, Volume: 156, Issue:2 Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Over	2010
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Translational research : the journal of laboratory and clinical medicine, 2010, Volume: 156, Issue:2 Topics: Adult; Chromatography, High Pressure Liquid; Deferiprone; Deferoxamine; Female; Ferric Compounds; Hu	2010
Pathogenesis and management of iron toxicity in thalassemia. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents;	2010
Deferiprone. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Liver; Pyridones; Randomized Control	2010
Combined iron chelation therapy. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Combinations; Ferritins; Humans	2010
Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. Pediatric blood & cancer, 2010, Dec-15, Volume: 55, Issue:7 Topics: Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Aspartate Aminotransferases; Chelation	2010
Increased oxidative stress and iron overload in Jordanian β-thalassemic children. Hemoglobin, 2011, Volume: 35, Issue:1 Topics: beta-Thalassemia; Case-Control Studies; Catalase; Child; Child, Preschool; Deferoxamine; Enzyme Assa	2011
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2011, Jul-06, Volume: 13 Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female;	2011
Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Annals of hematology, 2012, Volume: 91, Issue:7 Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Child; Cross-Sectional Studies; Deferoxamine	2012
Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload. European journal of haematology, 2012, Volume: 88, Issue:5 Topics: Child, Preschool; Deferoxamine; Female; Humans; Iron Overload; Male; Transfusion Reaction	2012
Desferrioxamine-related ocular toxicity: a case report. Indian journal of ophthalmology, 2012, Volume: 60, Issue:4 Topics: Adult; beta-Thalassemia; Deferoxamine; Diagnosis, Differential; Dose-Response Relationship, Drug; El	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen	2012
Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients. Transfusion, 2013, Volume: 53, Issue:8 Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Cost-Benefit Analysis; Cross-Sectional Stu	2013
Pulmonary iron overload in thalassemia major presenting as small airway disease. Acta haematologica, 2002, Volume: 108, Issue:1 Topics: Adult; Airway Obstruction; beta-Thalassemia; Biopsy; Chelation Therapy; Combined Modality Therapy; D	2002
Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2002, Volume: 35, Issue:11 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferoxamine; Femal	2002
Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clinical and laboratory haematology, 2003, Volume: 25, Issue:2 Topics: Acetylglucosaminidase; Adolescent; Adult; Aged; Albuminuria; beta 2-Microglobulin; beta-Thalassemia;	2003
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy. Haematologica, 2003, Volume: 88, Issue:11 Topics: Aged; Anemia, Refractory; Deferoxamine; Echocardiography; Fatal Outcome; Heart Diseases; Heart Ventr	2003
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Annals of hematology, 2004, Volume: 83, Issue:7 Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D	2004
Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients. British journal of haematology, 2004, Volume: 124, Issue:3 Topics: Adolescent; Adult; beta-Thalassemia; Case-Control Studies; Deferoxamine; Female; Ferritins; Humans;	2004
Complications of beta-thalassemia major in North America. Blood, 2004, Jul-01, Volume: 104, Issue:1 Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies;	2004
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood, 2004, Jul-01, Volume: 104, Issue:1 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferoxamine; Female; Humans; Male; Physical	2004
Desferrioxamine related maculopathy: a case report. American journal of hematology, 2004, Volume: 76, Issue:4 Topics: Aged; Aged, 80 and over; Atrophy; Deferoxamine; Diagnosis, Differential; Female; Glaucoma, Open-Angl	2004
Adherence to deferoxamine therapy: heeding Hippocrates and Osler. American journal of hematology, 2004, Volume: 76, Issue:4 Topics: Adult; Child; Cross-Over Studies; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Needle	2004
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 2004, Volume: 89, Issue:10 Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe	2004
Transfusion haemosiderosis inspite of regular use of desferrioxamine: case report. East African medical journal, 2004, Volume: 81, Issue:6 Topics: Adult; Anemia, Aplastic; Deferoxamine; Fatal Outcome; Female; Hemosiderosis; Humans; Iron Chelating	2004
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical	2005
Methods for noninvasive measurement of tissue iron in Cooley's anemia. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Adult; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferoxamine; Female; Ferriti	2005
Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:12 Topics: Acoustic Impedance Tests; Adolescent; Adult; Anemia, Hemolytic, Congenital; beta-Thalassemia; Chelat	2005
New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert opinion on emerging drugs, 2006, Volume: 11, Issue:1 Topics: beta-Thalassemia; Carboxylic Acids; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Design	2006
A case of rhesus hemolytic disease with hemophagocytosis and severe iron overload due to multiple transfusions. Journal of pediatric hematology/oncology, 2006, Volume: 28, Issue:5 Topics: Adult; Anemia, Hemolytic, Autoimmune; Cholestasis, Intrahepatic; Deferoxamine; Female; Humans; Infan	2006
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch	2006
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2. Hemoglobin, 2006, Volume: 30, Issue:2* Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod	2006
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studi	2006
Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Child; Combined Modality T	2006
Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Abortion, Eugenic; Adolescent; Adult; Blood Transfusion; Chelation Therapy; Combined Modality Therap	2006
Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Activities of Daily Living; Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Atti	2006
Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Attitude to Health; beta-Thalass	2006
Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha. Haematologica, 2006, Volume: 91, Issue:12 Suppl Topics: Anemia, Refractory; Anemia, Sideroblastic; Antibodies, Monoclonal; Apoptosis; Combined Modality Ther	2006
Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. American journal of hematology, 2008, Volume: 83, Issue:4 Topics: Adolescent; Adult; Anemia, Sickle Cell; Cardiomyopathies; Chelation Therapy; Child; Child, Preschool	2008
Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatric nephrology (Berlin, Germany), 2008, Volume: 23, Issue:6 Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Biomarkers; Blood Glucose; Case-Control Studies; C	2008
Desferal therapy in iron storage disease. The American journal of the medical sciences, 1967, Volume: 253, Issue:4 Topics: Adolescent; Adult; Anemia, Aplastic; Anemia, Sickle Cell; Deferoxamine; Female; Hemochromatosis; Hem	1967
Iron chelation with oral desferrioxamine. Lancet (London, England), 1980, Oct-11, Volume: 2, Issue:8198 Topics: Deferoxamine; Humans; Siderosis; Transfusion Reaction	1980
Ocular toxicity of high-dose intravenous desferrioxamine. Lancet (London, England), 1983, Jul-23, Volume: 2, Issue:8343 Topics: Adolescent; Adult; Cataract; Child; Child, Preschool; Dark Adaptation; Deferoxamine; Female; Follow-	1983
Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet (London, England), 1984, Feb-18, Volume: 1, Issue:8373 Topics: Deferoxamine; Heart Diseases; Humans; Iron; Thalassemia; Transfusion Reaction	1984
Iron overload in cardiac valvular disease and pure red cell aplasia: treatment with desferrioxamine. International journal of cardiology, 1984, Volume: 5, Issue:6 Topics: Anemia, Aplastic; Atrial Fibrillation; Cardiomegaly; Deferoxamine; Female; Hemosiderosis; Humans; Ir	1984
Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters. Haematologia, 1984, Volume: 17, Issue:1 Topics: Administration, Oral; Animals; Deferoxamine; Dose-Response Relationship, Drug; Drug Evaluation, Prec	1984
[Therapy of hemosiderosis with deferoxamine]. Deutsche medizinische Wochenschrift (1946), 1984, Nov-02, Volume: 109, Issue:44 Topics: Deferoxamine; Hemosiderosis; Humans; Injections, Intravenous; Iron; Life Expectancy; Liver; Transfus	1984
Vitamin C, desferrioxamine and iron loading anemias. Australian and New Zealand journal of medicine, 1984, Volume: 14, Issue:5 Topics: Anemia; Ascorbic Acid; Deferoxamine; Genes, Recessive; Hemochromatosis; Humans; Intestinal Absorptio	1984
[The treatment of post-transfusional hemochromatosis with chelating agents]. Revue medicale de Liege, 1981, Jun-01, Volume: 36, Issue:11 Topics: Adult; Chelating Agents; Deferoxamine; Edetic Acid; Hemochromatosis; Humans; Male; Pentetic Acid; Tr	1981
Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography. Birth defects original article series, 1982, Volume: 18, Issue:7 Topics: Adolescent; Ascorbic Acid Deficiency; Aspartate Aminotransferases; Child; Deferoxamine; Echocardiogr	1982
Therapy of HBsAg-negative chronic active hepatitis in transfusion-dependent thalassemia major. Birth defects original article series, 1982, Volume: 18, Issue:7 Topics: Aspartate Aminotransferases; Child; Child, Preschool; Deferoxamine; Hepatitis B; Hepatitis B Surface	1982
Editorial retrospective. Iron loading in thalassemia--five years with the pump. The New England journal of medicine, 1983, Feb-24, Volume: 308, Issue:8 Topics: Adolescent; Adult; Child; Deferoxamine; Humans; Iron; Thalassemia; Transfusion Reaction	1983
[Transfusion induced hypersiderosis in aplastic anemia--physiopathology and therapeutic aspects]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1983, Feb-01, Volume: 38, Issue:3 Topics: Anemia, Aplastic; Deferoxamine; Hemosiderosis; Humans; Infusions, Parenteral; Iron; Transfusion Reac	1983
Thalassemia. Progress in clinical and biological research, 1983, Volume: 127 Topics: Chelating Agents; Costs and Cost Analysis; Deferoxamine; Humans; Iron; Thalassemia; Transfusion Reac	1983
Current concepts in the overall management of thalassemia. Annals of the New York Academy of Sciences, 1980, Volume: 344 Topics: Biological Transport; Blood Transfusion; Chelating Agents; Deferoxamine; Erythrocyte Transfusion; Ex	1980
Evaluation of cardiac function in patients with thalassemia major. Annals of the New York Academy of Sciences, 1980, Volume: 344 Topics: Adolescent; Adult; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Heart; Heart Diseases; Hear	1980
Zinc deficiency developing in treatment for thalassaemia. Journal of the Royal Society of Medicine, 1982, Volume: 75, Issue:1 Topics: Child; Deferoxamine; Humans; Male; Pentetic Acid; Thalassemia; Transfusion Reaction; Zinc	1982
Improved pituitary gonadotrophin response in adult transfusional haemosiderosis following desferrioxamine treatment. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1982, Volume: 14, Issue:1 Topics: Deferoxamine; Gonadotropins, Pituitary; Hemosiderosis; Humans; Male; Middle Aged; Pituitary Function	1982
Ferrioxamine excretion in iron-loaded man. Blood, 1982, Volume: 60, Issue:2 Topics: Adult; Ascorbic Acid; Deferoxamine; Dose-Response Relationship, Drug; Feces; Hemosiderosis; Humans;	1982
[Long-term study in congenital refractory anemia and secondary siderosis]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1982, Apr-01, Volume: 37, Issue:7 Topics: Adolescent; Anemia, Aplastic; Deferoxamine; Dwarfism; Female; Hemosiderosis; Humans; Hypogonadism; H	1982
Desferrioxamine in the management of dialysis hemosiderosis. The International journal of artificial organs, 1982, Volume: 5, Issue:4 Topics: Deferoxamine; Hemosiderosis; Humans; Iron; Renal Dialysis; Transfusion Reaction	1982
Reduction of iron overload in thalassemia. Birth defects original article series, 1982, Volume: 18, Issue:7 Topics: Adolescent; Adult; Aging; Animals; Cell Separation; Child; Child, Preschool; Deferoxamine; Erythrocy	1982
[Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major]. Nouvelle revue francaise d'hematologie, 1982, Volume: 24, Issue:5 Topics: Adolescent; Adult; Blood Group Incompatibility; Child; Child Development; Child, Preschool; Deferoxa	1982
Early iron overload in beta-thalassaemia major: when to start chelation therapy? Archives of disease in childhood, 1982, Volume: 57, Issue:12 Topics: Child, Preschool; Deferoxamine; Hemochromatosis; Humans; Infant; Iron; Thalassemia; Transfusion Reac	1982
Continuous high-dose intravenous desferrioxamine treatment for iron overload. Israel journal of medical sciences, 1981, Volume: 17, Issue:5 Topics: Aged; Anemia, Aplastic; Deferoxamine; Erythrocyte Transfusion; Hemosiderosis; Humans; Infusions, Par	1981
Continuous intra-venous (CIV) infusion of desferrioxamine (DF) in a hemodialysed patient with transfusion siderosis. The International journal of artificial organs, 1981, Volume: 4, Issue:2 Topics: Adult; Deferoxamine; Humans; Infusions, Parenteral; Male; Renal Dialysis; Siderosis; Transfusion Rea	1981
Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload. European journal of pediatrics, 1981, Volume: 137, Issue:3 Topics: Adolescent; Anemia, Aplastic; Anemia, Sideroblastic; Child; Child, Preschool; Deferoxamine; Hemoside	1981
Transfusion therapy: its role in the anemias. Hospital practice, 1980, Volume: 15, Issue:6 Topics: Anemia; Blood Group Incompatibility; Blood Grouping and Crossmatching; Deferoxamine; Erythrocyte Tra	1980
[Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)]. Archives francaises de pediatrie, 1980, Volume: 37, Issue:4 Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Female; Ferritins; Hemosiderosis; Humans;	1980
Treatment of iron storage disorders. Drugs, 1980, Volume: 20, Issue:3 Topics: Anemia; Deferoxamine; Hemochromatosis; Humans; Iron; Liver Cirrhosis; Porphyrias; Skin Diseases; Tha	1980
Vitamin C and iron. The New England journal of medicine, 1981, Jan-15, Volume: 304, Issue:3 Topics: Administration, Oral; Adult; Animals; Ascorbic Acid; Ascorbic Acid Deficiency; Deferoxamine; Female;	1981
Hepatitis C virus infection and liver disease in children with thalassemia. Bone marrow transplantation, 1993, Volume: 12 Suppl 1 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Combined Modality T	1993
Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients. British journal of haematology, 1995, Volume: 89, Issue:4 Topics: Adolescent; Adult; Aged; Deferoxamine; Dose-Response Relationship, Drug; Female; Ferritins; Follow-U	1995
Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns. Leukemia & lymphoma, 1994, Volume: 15, Issue:1-2 Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Sideroblastic; Blood Transfusion; Chelation The	1994
Pulmonary function abnormalities in thalassemia major and the role of iron overload. American journal of respiratory and critical care medicine, 1994, Volume: 149, Issue:6 Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Blood Gas Analysis; Body Burden; Child; Deferoxami	1994
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. The New England journal of medicine, 1994, Sep-01, Volume: 331, Issue:9 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Confidence Intervals; Deferoxamine; F	1994
Desferrioxamine induced urinary iron excretion in thalassemia. Indian pediatrics, 1993, Volume: 30, Issue:6 Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Ferritins; H	1993
Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major. Australian and New Zealand journal of medicine, 1993, Volume: 23, Issue:6 Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Child; Deferoxamine; Electrocardiography; Fem	1993
[Post-transfusion hemochromatosis. Results of a study carried out in Blood Transfusion Centers. Analysis of 15 cases treated with subcutaneous perfusion of Desferal. Working group "Transfusion Techniques and Therapeutics"]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 1994, Volume: 1, Issue:1 Topics: Deferoxamine; France; Hemochromatosis; Humans; Injections, Subcutaneous; Perfusion; Retrospective St	1994
Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report. Bone marrow transplantation, 1993, Volume: 12 Suppl 1 Topics: Adolescent; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferoxamine; Ferritins;	1993
Cardiac study by dobutamine stress echocardiography in thalassemic patients. Bone marrow transplantation, 1993, Volume: 12 Suppl 1 Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modality Therapy; Deferoxami	1993
Liver iron overload and liver fibrosis in thalassemia. Bone marrow transplantation, 1993, Volume: 12 Suppl 1 Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Combined Modality Therapy; Deferoxami	1993
High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. American journal of hematology, 1996, Volume: 51, Issue:1 Topics: Adolescent; Adult; beta-Thalassemia; Catheters, Indwelling; Chelation Therapy; Deferoxamine; Drug Hy	1996
Management of iron overload with a disposable multi-day delivery system. American journal of hematology, 1996, Volume: 51, Issue:1 Topics: Adolescent; Catheters, Indwelling; Chelation Therapy; Child; Deferoxamine; Disposable Equipment; Hem	1996
Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients. Pediatric radiology, 1995, Volume: 25 Suppl 1 Topics: Adult; beta-Thalassemia; Body Height; Deferoxamine; Female; Follow-Up Studies; Hemosiderosis; Humans	1995
Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. American journal of hematology, 1996, Volume: 51, Issue:3 Topics: Adult; Deferoxamine; Erythropoiesis; Hemosiderosis; Humans; Male; Siderophores; Transfusion Reaction	1996
Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood, 1996, Jul-15, Volume: 88, Issue:2 Topics: Adolescent; Adult; beta-Thalassemia; Body Fluid Compartments; Chelation Therapy; Child; Deferoxamine	1996
The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. British journal of haematology, 1996, Volume: 94, Issue:2 Topics: Adolescent; Aged; Bone Marrow Diseases; Chromosome Aberrations; Deferoxamine; Erythropoietin; Female	1996
[Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major]. Sangre, 1995, Volume: 40, Issue:6 Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Combined Modality Therapy	1995
Pelvic osteomyelitis in a sickle-cell patient receiving deferoxamine. American journal of hematology, 1996, Volume: 53, Issue:4 Topics: Adolescent; Anemia, Sickle Cell; Chelation Therapy; Deferoxamine; Humans; Ilium; Injections, Subcuta	1996
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion, 1997, Volume: 37, Issue:2 Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Child; Deferoxamine; Erythropoiesis; Growth; Hemogl	1997
Desferrioxamine ototoxicity in an adult transfusion-dependent population. The Journal of otolaryngology, 1997, Volume: 26, Issue:2 Topics: Adult; Aged; Anemia, Sickle Cell; Audiometry; beta-Thalassemia; Deferoxamine; Drug Monitoring; Fanco	1997
Cardiac function during iron chelation therapy in adult non-thalassaemic patients with transfusional iron overload. European journal of haematology, 1997, Volume: 59, Issue:4 Topics: Adolescent; Adult; Aged; Aging; Antidotes; Ascorbic Acid; beta-Thalassemia; Chelating Agents; Corona	1997
Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy. Pediatric radiology, 1997, Volume: 27, Issue:12 Topics: Adolescent; Anemia, Sickle Cell; Catheterization, Central Venous; Chelation Therapy; Deferoxamine; F	1997
HBED: A potential alternative to deferoxamine for iron-chelating therapy. Blood, 1998, Feb-15, Volume: 91, Issue:4 Topics: Animals; Antidotes; Chelating Agents; Deferoxamine; Edetic Acid; Haplorhini; Iron Overload; Male; Ra	1998
Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Haematologica, 1998, Volume: 83, Issue:9 Topics: Adult; Aged; Chelating Agents; Chelation Therapy; Deferoxamine; Female; Hematologic Diseases; Hemato	1998
The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood, 2000, May-01, Volume: 95, Issue:9 Topics: beta-Thalassemia; Chelating Agents; Deferoxamine; Dietary Supplements; Drug Monitoring; Enzyme-Linke	2000
Site of subcutaneous desferrioxamine injection is the initial site of post-transfusion urticaria in multi-transfused beta-thalassaemia major patients. Clinical and laboratory haematology, 2000, Volume: 22, Issue:1 Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Child, Preschool; Deferoxamine; Humans	2000
Effect of transfusional iron overload on immune response. The Journal of infectious diseases, 2000, Volume: 182 Suppl 1 Topics: Adolescent; Adult; beta-Thalassemia; CD8-Positive T-Lymphocytes; Chelating Agents; Child; Child, Pre	2000
Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy. Transfusion science, 2000, Volume: 23, Issue:3 Topics: Chelating Agents; Deferoxamine; Drug Monitoring; Hemosiderosis; Humans; Iron; Transfusion Reaction	2000
ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood, 2001, Feb-15, Volume: 97, Issue:4 Topics: Animals; Benzoates; Bile; Cells, Cultured; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical;	2001
Progression of iron overload in sickle cell disease. Seminars in hematology, 2001, Volume: 38, Issue:1 Suppl 1 Topics: Adolescent; Adult; Anemia, Sickle Cell; Biopsy, Needle; Child; Child, Preschool; Cohort Studies; Def	2001
Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Seminars in hematology, 2001, Volume: 38, Issue:1 Suppl 1 Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Caregivers; Child; Data	2001
Incomplete cerebral infarctions are not silent. Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:2 Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Bone Marrow Transplantation; Brain Damage, Chr	2001
Yersinia enterocolitica as a cause of intra-abdominal abscess: the role of iron. Canadian journal of surgery. Journal canadien de chirurgie, 2001, Volume: 44, Issue:2 Topics: Abdominal Abscess; Abdominal Pain; Adult; Anti-Bacterial Agents; beta-Thalassemia; Chelating Agents;	2001
Intussusception due to Yersinia enterocolitica enterocolitis in a patient with beta-thalassemia. Archives of pathology & laboratory medicine, 2001, Volume: 125, Issue:11 Topics: beta-Thalassemia; Child, Preschool; Deferoxamine; Enterocolitis; Humans; Hypertrophy; Ileum; Intussu	2001
Blood and blisters: porphyria cutanea tarda in myelodysplastic syndrome. British journal of haematology, 2002, Volume: 116, Issue:1 Topics: Aged; Aged, 80 and over; Anemia, Refractory; Deferoxamine; Female; Hand Dermatoses; Humans; Iron Che	2002
Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients. European journal of haematology, 2001, Volume: 67, Issue:4 Topics: Adult; Chelating Agents; Chelation Therapy; Deferoxamine; Female; Ferritins; Humans; Infusion Pumps;	2001
Impact of thalassemia major on patients and their families. Acta haematologica, 2002, Volume: 107, Issue:3 Topics: Adolescent; Adult; beta-Thalassemia; Child; Cost of Illness; Deferoxamine; Diabetes Complications; E	2002
Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatric radiology, 2002, Volume: 32, Issue:7 Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Bone and Bones; Bone Diseases, Developmental	2002
Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet (London, England), 1977, May-07, Volume: 1, Issue:8019 Topics: Administration, Oral; Adolescent; Adult; Anemia, Sideroblastic; Ascorbic Acid; Child; Deferoxamine;	1977
Desferrioxamine and transfusional iron overload. Lancet (London, England), 1978, Mar-04, Volume: 1, Issue:8062 Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Hemosiderosis; Humans; Transfusion Reaction	1978
Prevention of iron loading in transfusion-dependent thalassaemia. Lancet (London, England), 1978, Jun-03, Volume: 1, Issue:8075 Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Deferoxamine; Dose-Response Relationship, D	1978
Subcutaneous desferrioxamine in homozygous beta-thalassaemia. Lancet (London, England), 1978, Nov-25, Volume: 2, Issue:8100 Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Deferoxamine; Hemosiderosis; Homozygote; Hu	1978
Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet (London, England), 1979, May-05, Volume: 1, Issue:8123 Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Anemia, Sideroblastic; Aspartate Aminotransferases; Child	1979
[Experience with desferrioxamine treatment by slow subcutaneous administration, in thalassemia]. Minerva pediatrica, 1979, May-31, Volume: 31, Issue:10 Topics: Adolescent; Adult; Child; Deferoxamine; Female; Humans; Injections, Intramuscular; Male; Siderosis;	1979
[Experience with desferrioxamine treatment by intravenous administration, in thalassemia]. Minerva pediatrica, 1979, May-31, Volume: 31, Issue:10 Topics: Child; Deferoxamine; Female; Humans; Infusions, Parenteral; Male; Siderosis; Thalassemia; Transfusio	1979
Increased risk of diabetes mellitus in beta- thalassemia major due to iron overload. Helvetica paediatrica acta, 1979, Volume: 34, Issue:3 Topics: Adolescent; Arginine; Blood Glucose; Child; Child, Preschool; Deferoxamine; Diabetes Mellitus, Type	1979
[The effect of desferrioxamine on the treatment of transfusion hemosiderosis--with special reference to the method of its administration (authors' transl)]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1977, Volume: 18, Issue:12 Topics: Adult; Aged; Anemia, Aplastic; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Male; Transfusion	1977
Treatment of iron overload in adults with continuous parenteral desferrioxamine. The American journal of medicine, 1977, Volume: 63, Issue:6 Topics: Adult; Aged; Ascorbic Acid; Biopsy, Needle; Deferoxamine; Female; Ferritins; Hemosiderosis; Humans;	1977
Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis. Transactions of the Association of American Physicians, 1977, Volume: 90 Topics: Adult; Anemia, Sideroblastic; Ascorbic Acid; Deferoxamine; Drug Administration Schedule; Female; Hem	1977
Iron burden in sickle cell anemia. The Journal of pediatrics, 1978, Volume: 92, Issue:4 Topics: Adolescent; Adult; Anemia, Sickle Cell; Body Burden; Child; Child, Preschool; Deferoxamine; Ferritin	1978
[Controlled desferrioxamine treatment of congenital anaemia and transfusion siderosis (author's transl)]. Deutsche medizinische Wochenschrift (1946), 1978, Aug-04, Volume: 103, Issue:31 Topics: Adolescent; Anemia, Aplastic; Child; Deferoxamine; Erythrocytes, Abnormal; Humans; Iron; Male; Sider	1978
Intensive iron-chelation in thalassaemia. British medical journal, 1978, Sep-16, Volume: 2, Issue:6140 Topics: Child; Child, Preschool; Deferoxamine; Humans; Infusions, Parenteral; Iron; Thalassemia; Transfusion	1978
Total management of thalassaemia major. Archives of disease in childhood, 1977, Volume: 52, Issue:6 Topics: Adolescent; Adult; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Humans; Hypersplenism; Infa	1977
Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine. Clinical nephrology, 1976, Volume: 6, Issue:1 Topics: Deferoxamine; Female; Hemosiderosis; Humans; Iron; Middle Aged; Renal Dialysis; Transfusion Reaction	1976
Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia. The Journal of pathology, 1975, Volume: 116, Issue:2 Topics: Adolescent; Adult; Age Factors; Biopsy; Child; Child, Preschool; Deferoxamine; Humans; Iron; Iron Ch	1975
Reassessment of the use of desferrioxamine B in iron overload. The New England journal of medicine, 1976, Jun-24, Volume: 294, Issue:26 Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Depression, Chemical; Humans; Infusions, P	1976
[Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)]. Archives francaises de pediatrie, 1992, Volume: 49, Issue:3 Topics: Acute-Phase Reaction; Adolescent; Adult; Catheters, Indwelling; Deferoxamine; Female; Heart Failure;	1992
Iron chelation. The Journal of the Association of Physicians of India, 1991, Volume: 39, Issue:9 Topics: Chelation Therapy; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron; Iron Chelating Agents;	1991
Cystic fibrosis in a black child with hemoglobin S-D disease. The American journal of pediatric hematology/oncology, 1990,Fall, Volume: 12, Issue:3 Topics: Black People; Child; Cystic Fibrosis; Deferoxamine; Female; Hemochromatosis; Hemoglobinopathies; Hem	1990
[Treatment of post-transfusion iron overload by deferoxamine]. Archives francaises de pediatrie, 1989, Volume: 46, Issue:2 Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Deferoxamine; Ferritins; Hemochromatosis; Humans; Tha	1989
Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children. European journal of pediatrics, 1989, Volume: 148, Issue:6 Topics: Adolescent; Child; Deferoxamine; Female; Ferric Compounds; Hemochromatosis; Humans; Infusions, Paren	1989
Transfusional iron overload in patients undergoing dialysis: treatment with erythropoietin and phlebotomy. The Journal of laboratory and clinical medicine, 1989, Volume: 114, Issue:2 Topics: Adult; Aged; Bloodletting; Deferoxamine; Erythropoietin; Female; Ferritins; Hematocrit; Humans; Iron	1989
Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. The Journal of pediatrics, 1986, Volume: 108, Issue:4 Topics: Adolescent; Adult; Anemia, Hemolytic, Congenital; Anemia, Sickle Cell; Anemia, Sideroblastic; Bindin	1986
Reappraisal of high-dose desferrioxamine therapy. Acta haematologica, 1986, Volume: 76, Issue:1 Topics: Deferoxamine; Hemosiderosis; Humans; Thalassemia; Transfusion Reaction	1986
Rapid excretion of gallium-67 isotope in an iron-overloaded patient receiving high-dose intravenous deferoxamine. American journal of hematology, 1988, Volume: 29, Issue:4 Topics: Adult; Cerebral Hemorrhage; Cerebral Ventricles; Deferoxamine; Drug Administration Schedule; Fever;	1988
[Effect of continuous subcutaneous infusion of deferoxamine in a boy with congenital hypoplastic anemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1988, Volume: 29, Issue:9 Topics: Anemia, Aplastic; Child, Preschool; Deferoxamine; Drug Evaluation; Erythrocyte Transfusion; Hemoside	1988
[Subcutaneous administration of deferoxamine in a patient with panmyelopathy and post-transfusion hemosiderosis]. Polskie Archiwum Medycyny Wewnetrznej, 1987, Volume: 78, Issue:1 Topics: Adult; Anemia, Aplastic; Deferoxamine; Hemosiderosis; Humans; Injections, Subcutaneous; Male; Transf	1987
Reduction in liver iron in hemodialysis patients with transfusional iron overload by deferoxamine mesylate. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1988, Volume: 12, Issue:1 Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Deferoxamine; Ferritins; Humans; Iron; Liver; Ren	1988
Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. The American journal of medicine, 1987, Volume: 83, Issue:6 Topics: Adolescent; Adult; Audiometry; Child; Child, Preschool; Deferoxamine; Hearing Loss; Hearing Loss, Hi	1987
Iron overload and mobilization in long-term hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1987, Volume: 10, Issue:4 Topics: Adult; Bone Diseases; Child; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Hemochromatos	1987
Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scandinavian journal of haematology, 1986, Volume: 36, Issue:5 Topics: Administration, Oral; Adult; Ascorbic Acid; Child; Deferoxamine; Dose-Response Relationship, Drug; D	1986
Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion. Experimental hematology, 1986, Volume: 14, Issue:10 Topics: Animals; Chelating Agents; Deferoxamine; Disease Models, Animal; Erythrocytes; Hemosiderosis; Hydrox	1986
Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis. The American journal of medicine, 1987, Volume: 82, Issue:2 Topics: Adult; Aluminum; Deferoxamine; Feces; Female; Hemosiderosis; Humans; Iron; Iron Deficiencies; Osteom	1987
The chronically transfused patient: advances in treatment. Hospital practice (Office ed.), 1985, Jul-15, Volume: 20, Issue:7 Topics: Acquired Immunodeficiency Syndrome; Adult; Blood Grouping and Crossmatching; Blood Transfusion; Chil	1985
Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Archives of internal medicine, 1985, Volume: 145, Issue:7 Topics: Adult; Anemia; Blood Glucose; Deferoxamine; Glucose Tolerance Test; Hemosiderosis; Humans; Iron; Iro	1985
High-dose desferoxamine and Diamond-Blackfan anemia. Annals of internal medicine, 1986, Volume: 104, Issue:4 Topics: Adolescent; Anemia; Deferoxamine; Heart Failure; Humans; Infusions, Parenteral; Thalassemia; Transfu	1986
Red cell ghost-entrapped deferoxamine as a model clinical targeted delivery system for iron chelators and other compounds. Bibliotheca haematologica, 1985, Issue:51 Topics: Deferoxamine; Erythrocyte Membrane; Humans; Iron; Pharmaceutical Vehicles; Transfusion Reaction	1985
Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major. Annals of the New York Academy of Sciences, 1974, Volume: 232, Issue:0 Topics: Administration, Oral; Adolescent; Adult; Age Factors; Ascorbic Acid; Child; Child, Preschool; Defero	1974
Long-term desferrioxamine therapy in thalassemia. Annals of the New York Academy of Sciences, 1974, Volume: 232, Issue:0 Topics: Adolescent; Ascorbic Acid; Child; Child, Preschool; Cyprus; Deferoxamine; Drug Synergism; Humans; Ir	1974
[Treatment of hypersiderosis with Desferal]. Vutreshni bolesti, 1972, Volume: 11, Issue:6 Topics: Deferoxamine; Hemosiderosis; Humans; Iron; Transfusion Reaction	1972
Editorial: Thalassemia major: a problem of iron overload. Annals of internal medicine, 1974, Volume: 81, Issue:2 Topics: Ascorbic Acid; Chelating Agents; Child; Child, Preschool; Deferoxamine; Humans; Intestinal Absorptio	1974
EXcretion and distribution of iron during chronic deferoxamine therapy. Blood, 1971, Volume: 38, Issue:5 Topics: Anemia, Aplastic; Bone Marrow; Bone Marrow Examination; Child; Chromium Isotopes; Deferoxamine; Foli	1971
[Present aspects of the treatment of hemochromatosis (apropos of 100 observations)]. Annales de medecine interne, 1971, Volume: 122, Issue:12 Topics: Adult; Alcoholic Intoxication; Bloodletting; Chelating Agents; Chondrocalcinosis; Deferoxamine; Diab	1971
The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion. British journal of haematology, 1969, Volume: 17, Issue:6 Topics: Ascorbic Acid; Ascorbic Acid Deficiency; Deferoxamine; Hemochromatosis; Humans; Iron; Leukocytes; Ma	1969
[Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children]. Marseille medical, 1967, Volume: 104, Issue:4 Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic; Child; Child, Preschool; Deferoxamine; Female; Hemo	1967
[Iron storage disease]. Munchener medizinische Wochenschrift (1950), 1967, Mar-31, Volume: 109, Issue:13 Topics: Adult; Anemia; Child; Deferoxamine; Female; Hemochromatosis; Humans; Iron; Liver Diseases; Male; Mid	1967
Congenital erythroblastic hypoplasia. Treatment of transfusion hemosiderosis with desferrioxamine B. Henry Ford Hospital medical journal, 1968,Summer, Volume: 16, Issue:2 Topics: Adolescent; Adult; Anemia, Aplastic; Child; Child, Preschool; Deferoxamine; Hemosiderosis; Humans; I	1968
Effect of desferrioxamine B. A new iron eliminating agent, on cases of secondary haemosiderosis in children. The Journal of tropical medicine and hygiene, 1969, Volume: 72, Issue:1 Topics: Child; Child, Preschool; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Liver; Male; Siderosis;	1969
[First results of a new iron chelating agent in the treatment of post-transfusional hemochromatosis]. Archives francaises de pediatrie, 1965, Volume: 22, Issue:4 Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Hemochromatosis; Humans; Transfusion Reaction	1965
Transfusion hemosiderosis. Report of a case treated with desferrioxamine-B. Journal of the Iowa Medical Society, 1965, Volume: 55, Issue:6 Topics: Adult; Anemia, Sideroblastic; Deferoxamine; Hemosiderosis; Humans; Male; Transfusion Reaction	1965
[Use of desferrioxamine B in the treatment of post-transfusion hypersiderosis]. Marseille medical, 1965, Volume: 102, Issue:7 Topics: Adolescent; Anemia, Hemolytic; Child; Child, Preschool; Deferoxamine; Female; Humans; Male; Siderosi	1965

Intervention	percentage of participants (Geometric Mean)
	Month 6	Month12	Month 18	Month 24
All Participants	12.50	19.23	33.33	47.22